

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

**ANNOUNCEMENT ON THE RESOLUTION OF THE BOARD OF DIRECTORS
APPLICATION FOR FULL CIRCULATION OF
UNLISTED SHARES OF THE COMPANY**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) pursuant to Rule 13.51 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

APPLICATION FOR FULL CIRCULATION OF UNLISTED SHARES OF THE COMPANY

Reference is made to the Guidelines on Application for “Full Circulation” of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請“全流通”業務指引》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 and further amended on August 10, 2023, and the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) issued by the CSRC on February 17, 2023 regarding the procedures to apply for full circulation of shares by companies whose H shares are listed on the Stock Exchange.

The Company may, subject to shareholders’ request and in compliance with the relevant laws, regulations, rules and normative documents of the People’s Republic of China as well as the Listing Rules, submit an application to the CSRC for the full circulation of domestic unlisted shares.

The number of shares and respective percentage for which the participating shareholders have applied for full circulation are set out below:

No.	Name of shareholder	Current number of shares held in the Company (share)	Shareholding percentage of the total share capital (%)	Number of shares proposed for full circulation (share)	Percentage of full circulation in the total share capital (%)
1	Shanghai Xin Sheng De Yuan Enterprise Management Centre (Limited Partnership)* (上海馨升德源企業管理中心(有限合伙))	34,798,296	9.5446	6,798,296	1.8647
2	Shanghai Haidai Botai Enterprise Management Centre (Limited Partnership)* (上海海岱帛泰企業管理中心(有限合伙))	24,475,926	6.7133	12,237,963	3.3567
3	Sichuan Xintongde Big Data Industry Venture Capital Partnership (Limited Partnership)* (四川新同德大數據產業創業投資合夥企業(有限合伙))	1,911,698	0.5243	955,849	0.2622
Total				<u>19,992,108</u>	<u>5.4835</u>

The resolution of this full circulation proposal shall remain valid within the validity period of the power of attorney issued by the participating shareholders applying for full circulation. In the event that such shareholders reissue a power of attorney to extend the authorization period, the validity period of this full circulation proposal resolution shall be extended accordingly.

The above proposal has been duly approved by the Board.

The proposal does not need to be submitted to the general meeting for consideration.

The full circulation is subject to other relevant procedures as required by the Stock Exchange, the CSRC and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 26 May 2025

As at the date of this notice, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.